NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Lento Bio, Inc.

Lento Bio, Inc.

Private
Syracuse, New YorkHealthcare & Life Scienceshttps://lentobio.com/

Last Round

Seed

May 30, 2023

Total Funding Raised

$3.58M

Company Overview

Lento Bio, Inc. is a biotechnology company developing small-molecule eyedrops to treat presbyopia by restoring ocular lens flexibility.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologypresbyopia treatmentsmall-molecule therapeuticsophthalmic drugdrug discoveryanti-aging medicineeyedropslongevity biotechclinical trialsprodruginvestigational new drugINDvision correctionpreclinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lento Bio, Inc. Comparables

Compare Lento Bio, Inc. with similar companies based on industry and business-model similarity.

Lento Bio, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Glaukos Corporation
74%
Novartis
73%
Orasis Pharmaceuticals
70%

Lento Bio, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 30, 2023
Pre SeedSep 6, 2022

Key People

Founding team and executive leadership

Kris Barnes

Chief Executive Officer

Executive Team

Lento Bio, Inc. Investors

Notable investors and investment history

Lento Bio, Inc. investors
InvestorRounds
Excell PartnersSeed
Richmond View VenturesPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 30, 2023

    $2.9M round led by Excell Partners and Ichor Life Sciences

  • Sep 6, 2022

    $680K round led by Ichor Life Sciences.

Lento Bio, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Lento Bio, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Lento Bio, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSyracuse, New York
Employee Range3
Year Founded2022
Last FundingMay 30, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.